MicroRNAs are involved in the regulation of various pathophysiological processes such as immune regulation and cancer. Next-generation sequencing methods enable us to monitor their presence in various types of samples but we need flexible methods for validating datasets generated by high throughput methods.
Introduction
MicroRNAs (miRNAs) are short 18-25 nucleotide-long, single stranded, non-coding RNA molecules (1) . MiRNAs act as post-transcriptional regulators of gene expression through induction of translational repression or RNA decay (2) . MiRNAs play an important role in a wide range of normal physiological and pathological processes (3) (4) . Aberrantly expressed miRNAs contribute to the development of various human disorders including cancers, neurodegenerative disorders, and autoimmune diseases (5) (6) .
Unlike mRNAs, miRNAs are highly stable and well preserved RNA molecules in formalinfixed paraffin-embedded (FFPE) samples and different body fluids including plasma, saliva and urine (7) (8) (9) . The high stability as well as their disease-specific expression pattern renders miRNAs suitable for biomarkers in molecular diagnostic applications. Recently, miRNAs have been investigated as potential diagnostic and prognostic markers in patients suffering of cancer and autoimmune diseases by using samples of various origin, like FFPE, plasma, and urine (10) (11) (12) (13) . Interestingly, a miRNA expression profile is equally useful for identifying tissue origin of tumors, subtype classifications of different cancers, prediction of clinical outcome, and selection of patients for targeted therapy (14) (15) (16) (17) (18) (19) .
Stem-loop RT-qPCR is a widely used technique for detection and quantification of mature miRNAs (20) . This method includes two steps: 1. miRNA specific stem-loop RT primerbased reverse transcription, and 2. quantification of product using conventional TaqMan TM assay with miRNA specific TaqMan TM probe and forward primer. This method enables us to quantify mature miRNA expression levels from nanograms of total RNA (20) . A simplified setup of stem-loop RT-qPCR uses a general stem-loop primer specific probe from the Universal Probe Library (UPL, Roche Applied Science) for quantification of RT products without loss of specificity and efficiency (21) . More recently, we developed a novel UPL probe-based stem-loop RT-qPCR assay design software (MiRNA Primer Design Tool, freely available online at: http://genomics.dote.hu:8080/mirnadesigntool/) that enables anyone to design the stem loop and specific primers needed for the assay. The MiRNA Primer Design Tool was validated in various species and experimental conditions (22) . The method broadens the application of the stem-loop primer-based miRNA quantitation to virtually any species or variant of small regulatory RNA molecules.
Here we present a detailed protocol for a UPL probe-based stem-loop RT-qPCR assay. We used this method to quantify hsa-miR-515-3p, hsa-miR-325, and hsa-miR-155 using the small nucleolar RNA RNU43 as a normalization control. Human urines from healthy pregnant donors as well as FFPE samples from patients diagnosed with colorectal cancer were analyzed using the method described here.
Materials

Urine samples
Urine samples were collected from pregnant women during a prospective study in the Department of Obstetrics and Gynecology, University of Debrecen, Hungary. Samples were collected according to rules and regulations of the University of Debrecen, Medical and Health Science Center, with the approval of the local ethics committee (file number: 
Methods
Sample preparation and requirements
Collected urine samples should be stored temporarily at 4 °C. Samples are centrifuged at 3,000 xg for 10 min to remove cellular debris. The supernatant is transferred to 1.5 ml prelabeled screw tubes (sterile), and stored at -75 to -80 °C.
Regarding your FFPE samples: use only tumor blocks with malignant cell content higher than 30%. A dedicated pathologist should evaluate the tumor cell content of the paraffin embedded blocks. For each sample to be measured by QPCR, miRNA isolation should be carried out from five pieces of 4 !m-thick FFPE tumor slices and their adjacent non-tumorous tissues. 2. Pour the mixture into a High Pure filter tube.
3. Place your filter tube into a clean 1.5 ml microcentrifuge tube.
4. Centrifuge at 15,000 xg for 1 min at room temperature. Collect the flow-through in a clean 1.5 ml microcentrifuge tube.
Add 200 µl Binding
Enhancer to the flow-through, and mix well by vortexing. This fraction contains your microRNAs.
6. Add the mixture to a new High Pure filter tube.
7. Centrifuge at 15,000 xg for 1 min.
8. Discard the flow-through.
9. Add 500 µl of Wash Buffer and centrifuge columns at 15,000 xg for 1 min.
10. Repeat the washing steps 8 and 9.
11. Transfer High Pure Filter columns into a new collection tube and centrifuge at 15,000 xg for 2 min to completely dry the filter fleece. 14. Centrifuge at 15,000 xg for 1 min to elute the purified miRNAs.
15. Store samples below -20°C.
16. For miRNA isolation from higher amount of urine, see Note 8.
miRNA preparation from FFPE samples
Tumor slices from FFPE (formalin-fixed, paraffin-embedded) blocks can be obtained by microtome dissection and should be collected in 1.5ml microcentrifuge tubes as shown in Figure 1 . Five slices of 4 µm thickness should be combined in one microcentrifuge tube (see Note 9). For nucleic acid isolation, Xylene deparaffinization is used with subsequent washing by absolute ethanol. The deparaffinization steps should be performed 4-5 times to remove all the paraffin from samples. All steps of deparaffinization are recommended to be done under a chemical fume hood; solutions can be stored at room temperature.
( The yield of isolated miRNAs is donor dependent. Table 1 (Table 1) 
Quantification of miRNA by qPCR
For quantification of specific miRNAs, the first step of cDNA synthesis is followed by PCR amplification using the Real Time Quantitative method (qPCR). Design primers using the UPL probe-based stem-loop quantitative PCR assay design software located at: http://genomics.dote.hu:8080/mirnadesigntool/ (see Notes 2, 18, 19).
cDNA Synthesis:
Option A: recommended for miRNA with low or unknown expression levels Transcribe miRNAs using the Transcriptor First strand cDNA Synthesis kit and a final stemloop primer concentration of 50 nM. Use miRNA templates diluted to 10 ng/µl. Mix the following components per sample:
• We quantified miR-155 using this protocol and RNU43 as endogenous control. Our results correlate with previously published results (23) and suggest that in colorectal cancer increased levels of miR-155 might predict a better overall survival (OS) and disease-free survival (DFS) after treatment with anti-EGFR therapy. Results of the measurements are presented in Figure  4 . Due to the low number of samples (five independent samples per group), the presented results are not statistically significant and further investigation is needed. • Select your target miRNA sequence from mirBase (http://mirbase.org/) or from your next-generation sequencing dataset.
(E.g. hsa-mir-155: UUAAUGCUAAUCGUGAUAGGGGU). Use the identified sequence to design your assay at: http://genomics.dote.hu:8080/mirnadesigntool/ Useful information and details on how to use the software have been collected and stored at our dedicated website: http://genomics.med.unideb.hu/en/researchinterest/mirna-research. The MiRNA Primer Design Tool can be used freely under GNU/GPL license and installed on local servers from the following location: https://github.com/lbalintatmedunidebhu/mirnaprimerdesigntool • During selection of your target, perform a sequence search in the miRBase database to idetify microRNAs with similar sequences. If similar sequences on the 3' end are present, evaluate your assays for differences in the other regions and consider using alternative methods for detection.
• Order your stem loop oligo by HPLC purification. All other oligos used can be of standard desalted purification. ! 3. Always work with samples kept on ice. 4. Work in RNase-free conditions. 5. Always wear gloves. 6. Use only nuclease-free water. 7. Use RNase-free plasticware. 8. A higher amount of body fluid can be used if the miRNA concetration is too low. It is important to keep the same proportion of urine sample and Binding Buffer. For example, add 920 µl Binding Buffer to 450 µl urine, and repeat the binding steps to the column (steps 5 to 8). 9. During microtome dissection of the FFPE blocks, carefully clean tweezers with nucleasefree water and 70% ethanol to exclude ribonucleic acid transfer and contamination between samples. 10. Xylene should be discarded according to the local rules of waste management. Xylene is an organic solvent and should be treated as a chemically hazardous waste. 11. To remove all the supernatant during deparaffinization, additional centrifugation steps can be performed. 12. The Agilent small RNA kit contains a highly viscousus gel and, therefore, it is essential to pipette carefully. 13. If your sample contains significant amounts of tRNA then you will observe a 60 nt band in chromatogram of the Agilent Bioanalyzer run (24). 14. Specific miRNA concentrations can be measured only by an Agilent Bioanalyzer miRNA microchip. Due to the lower sensitivity, Nanodrop or Qubit systems are not appropriate. 15. If starting with a sample isolated from cells or tissues, the initial material should be between 5 ng and 50 ng of total RNA per RT reaction. This value stands for total RNA isolated by Trireagent. The concentration of total RNA mentioned here was measured by Nanodrop or Qubit systems due to the fact that beside the miRNA-s it contains all the other RNA fractions of a cell. 16. When using a specific miRNA isolation protocol, this starting material can be much lower and should be optimized for each sample type. 17. Conventional, non miRNA optimized column-based RNA purification methods are not suitable for microRNA purification since they are optimized for larger RNA molecules and the low molecular weight fraction of miRNA-s are not bound to the column. enzyme. Your NAC control should be at least a 3.33-C P higher value (meaning lower signal) than your control. Some background noise is acceptable but it should be less than 10% of your signal (3.33 C P would mean 10% signal with an optimal PCR efficiency). 22. You can test efficiency of your qPCR by performing a qPCR on a dilution series of 10-fold dilutions steps that cover five orders of magnitude. 23. At the qPCR step, always perform a No Templare control (NTC) by replacing your reverse transcribed sample with nuclease-free water. 24. qPCR step should be performed in triplicate (three technical replicates). 25. Normalizers should be carefully selected by measuring their expression levels across several samples used in your experiment. Usually small nucleolar RNAs (snoRNAs) and nuclear RNAs like U6 can be used after careful consideration. 26. Normalization should be performed with the delta delta !!C T method !"#$. 27. If working with body fluids, you can normalize your sample to a relevant marker that reflects the changes in the concentration of the body fluid e.g. total protein concentration, density. 28. If working with body fluids, the purification step can be controlled by adding spike-in artificial microRNA molecules to the sample. 29. Synthetic RNA molecules can be used for carefully monitoring the efficiency of your reactions and to generate standard curves. If using synthetic RNA molecules as positive controlls for your reaction, order them separately from your assay components in order to avoid cross contamination at the manufacturing site. Dissolve them under a chemical hood. Keep them in separate locations compared than your assays, reagents and samples. The danger of contaminating your reagents with traces of the amplicon is extremely high. Sample name column indicates the volume of urine used for miRNA purification..
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